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relationship between the severity of diastolic dysfunction, and get
plasma NT-proBNP in the diagnosis of diastolic heart failure most
good community values.
METHODS The study is outpatient or inpatient treatment of non-
systolic heart failure in patients with hypertension 61 cases were
divided into three groups: no clinical signs and symptoms of heart
failure, echocardiography without diastolic dysfunction group I;
clinical None signs and symptoms of heart failure, echocardiographic
diastolic dysfunction group II; clinical signs and symptoms of heart
failure, echocardiographic diastolic dysfunction group III. In 20
healthy control group. All patients enrolled in clinical data are
collected to determine the presence or absence of heart failure, and
cardiac function NYHA classiﬁcation. 24 hours of admission or treat-
ment echocardiography expert to determine whether the diastolic
dysfunction and diastolic function of the extent of becoming divided
into four weight: I level (normal diastolic function), grade II (impaired
relaxation), III grade (pseudo- normalization ﬁlling), grade IV
(restrictive ﬁlling). Admission or treatment plasma NT-proBNP con-
centrations within 24 hours. Comparison between different experi-
mental groups, between different classiﬁcation of diastolic function,
plasma NT-proBNP levels between different NYHA class; evaluate the
relationship between echocardiographic indices of diastolic function
and plasma NT-proBNP for; were constructed NT-proBNP diagnostic
diastolic dysfunction and diastolic ROC curve of heart failure, and
were the best diagnostic cutoff value.
RESULTS The area under the ROC curve of plasma NT-proBNP diag-
nosis of diastolic heart failure (AUC) was 0.886 (95% CI 0.818-0.954,
P ¼ 0.000). Plasma NT-proBNP when 112.45pg/ml, diastolic heart
failure diagnostic sensitivity 94.0%, speciﬁcity 81.8%, positive pre-
dictive value of 72.7%, negative predictive value of 94.6%.
CONCLUSIONS The plasma NT-proBNP for diagnosis of diastolic heart
failure is valuable.
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Predicting Value of Biomarkers for Short-Term Outcomes in Acute Heart
Failure
Rongrong Gao, Xinli Li
The First Afﬁliated Hospital of Nanjing Medical University
OBJECTIVES B-type natriuretic peptide (BNP) and N-terminal pro-B-
type natriuretic peptide (NT-proBNP) are increasingly being used to
guide the management of acute heart failure (AHF) patients. This
study aims to explore some new biomarkers providing predicting
values for short term prognosis in patients with AHF.
METHODS A total of 206 patients with AHF were enrolled and fol-
lowed for 3 months. Baseline level of complete blood count, complete
biochemistry, D-dimer and NT-proBNP were measured at admission
or the following morning. Primary endpoints of the study were car-
diovascular (CV) events, deﬁned as cardiac death and/or readmission
for AHF.
RESULTS During the 90-day follow-up period, 15 patients died and 10
patients were re-hospitalized due to worsening of heart failure
(12.14%). Red cell distribution width (RDW), D-dimer and NT-proBNP
were signiﬁcantly higher in the patients who had a CV events at the
90-day (p < 0.001). The area under receiver operating characteristic
(ROC) curve (AUC) of NT-proBNP, D-dimer and RDW for predicting CV
events by 90- day was 0.806, 0.887 and 0.754. Kaplan-Meier survival
curve for 90-day CV events showed that patients with a D-dimer level
> 1.1mg/dL and NT-proBNP > 2262.0pg/mL were at high risk (p <
0.001) for short-term outcomes of AHF.
CONCLUSIONS D-dimer could be as a new biomarker combined with
NT-proBNP for predicting early prognostic value to cardiovascular
events of AHF.
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Resveratrol protects the heart from sepsis without systemically
anti-inﬂammatory effect
Tao Bai,1,2 Fan Wang,3 Lu Cai,2 Yang Zheng1
1Cardiovascular Center, The First Hospital of Jilin University,
Changchun, China; 2KCHRI of Department of Pediatrics, the University
of Louisville, KY, USA; 3Department of Infective Disease, People’s
Hospital of Jilin Province, Changchun, China
OBJECTIVES Resveratrol can protect the heart from sepsis, but the
detailed mechanism remains unknown; therefore, we try to explore
the mechanism.METHODS FVB and C57BL/6J male mice (age: 8 weeks; body weight:
20-25g) were subjected to lipopolysaccharide (LPS) injection at 6 mg/
kg to set up a sepsis model. One study included 5 groups: Group 1
(control mice); Group 2 (intraperitoneal injection with LPS); Group 3
(treated with resveratrol only for 3 days); Group 4 (treated with
resveratrol for 3 days before LPS); Group 5 (treated with LPS and
resveratrol at same time). These mice were sacriﬁced at 48 h after LPS
treatment. The dose of resveratrol was 20 mg/kg/d. Serial echocar-
diograms were performed to assess cardiac function.
RESULTS In both strains of mice, LPS injection could signiﬁcantly
decrease the left ventricular EF% from 6 to 48 hour. For resveratrol
prevention study, we found that tumor necrosis factor alpha (TNF-a)
levels in plasma and heart tissue were signiﬁcantly increased at 6 h
after LPS injection in groups 2, 4, and 5, compared to the groups 1 and
3. Among the groups 2, 4 and 5 there was no signiﬁcant difference.
CD45 is a pan-leukocyte marker, heart wax section immunohisto-
chemistry staining for CD 45 shows no difference in all groups. Using
immune blot and ELISA to assess the ratio of cleaved caspase 3 to
caspase 3 and plasma level of troponin I, markers for cardiac cell
apoptosis and injury, respectively, showed no difference in all groups,
which indicates that cardiac dysfunction in sepsis is not due to cardiac
cell loss. Time-course comparison between FVB and C57BL/6J mice,
we found that C57BL/6J mice was more susceptible to FVB mice since
the former showed a signiﬁcant decrease (more than 50%) in EF%
while FVB mice showed about 40% decrease in EF%. However, car-
diac dysfunction of C57BL/6J mice showed a faster recovery from 6 to
24 hour compared to FVB that recovered from 6 to 48 hours.
CONCLUSIONS Resveratrol protection of the heart from sepsis is not
due to its prevention of LPS-induced inﬂammation. Since resveratrol
is a multiple bioactive natural compound, we should focus other
mechanisms to explore how resveratrol protect heart from sepsis in
the future studies.
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The Correlation between Cardiac function in patients with different
classiﬁcation levels of serum NT-proBNP and cardiac function
Zhiqing Fan,1 Pinghui Sun2
1Department of Cardiology, Daqing Oil Field General Hospital, China;
2Jilin University college of public health statistics teaching and
research, Changchun, China
OBJECTIVES To observe correlation between the standard of N-ter-
minal pro-B-type natriuretic peptide (NT-proBNP) and cardiac func-
tion in different NYHA classiﬁcation, LVEF and LVED.
METHODS For the 83 patients of heart failure in hospital, to assay
their NT-proBNP of blood serum by enzyme-linked immunosorbent
assay (ELISA) and determine their LVEF and LVED by UCG. To analyse
the correlation of patients’ NT-proBNP, the different cardiac func-
tional grading and the indexes above-mentioned.
RESULTS (1) Different NYHA cardiac function classiﬁcation levels of
serum NT-proBNP levels was signiﬁcantly. Its level is positively
correlated with cardiac function. (2) NT-proBNP is negatively corre-
lated with LVEF and positively correlated with the LVED.
CONCLUSIONS NT-proBNP measurement is one of the methods of
effective assistance in clinical diagnosis of heart failure, on the whole
reﬂect the severity of heart failure.
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Altitude difference of HMGB1, Fetuin-A in the patients with congestive
heart failure and effects on ventricular remodeling
Aiqi Xi, Guofeng Li
the People’s Hospital of Oinghai Province
OBJECTIVES Inﬂammation and dystrophic calciﬁcation have been
associated with cardiovascular disease (CVD) and chronic heart failure
(CHF), changes in pathophysiological functions are reported during
sea level altitude; however, Few study have explored altitude differ-
ence(2260m, 3300m) of change levels of serum high mobility group
box 1 protein (HMGB1), Fetuin-A in patients with congestive heart
failure and effects on ventricular remodeling. The aim of the present
study was to evaluate the effect the altitude difference explore on
HMGB1, Fetuin-A, and to study the relationship between changes of
HMGB1, Fetuin-A and left ventricular mass index (LVMI), mean wall
stress (MWS) and cardiac function.
METHODS A total of 129 consecutive patients with CHF with matched
age and sex were enrolled, and CHF patients were divided into high
altitude group (3300m) (n¼ 62) and moderate altitude group (2260m)
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were measured by ELISE. Left ventricular ejection fraction (LVEF) by
echocardiography, LVMI and MWS were calculated.
RESULTS The level of Serum HMGB1 and LVMI, MWS in CHF patients
lived at high altitude were higher than those at moderate altitude
[(42.877.86) pg/ml vs (26.755.22) pg/ml, (189.79.5) vs (96.38.4)
g/m2 and (476.214.9) vs (304.713.5) dynes x103/cm2, respectively,
all p<0.01].and the level of Fetuin-A was on the contrary [(1.15 0.32)
g/L vs ( 2.38 0.56) g/L, p<0.01]. It was found that LVMI, MWS has a
positive correlation withthe level of HMGB1 (P<0.01), and a negative
correlation With the level of Fetuin-A (P<0.01).
CONCLUSIONS ventricular remodeling in CHF change With the alti-
tude level severely. The changes LVMI and MWS were more related to
higher level of HMGB1 and lower level of Fetuin-A. At high altitude,
increasing in the level of HMGB1 and decreasing in the level of Fetuin-
A play roles in pathophysiological and pathogenetic mechanism of
ventricular remodeling in CHF, and correlated with the severity de-
gree of ventricular remodeling in CHF.
GW26-e1012
The relationship between bone mineral density and left ventricular
diastolic function in elderly hypertension patients
Zhiheng Chen, Pengqiang Zhang
the second afﬁliated hospital of Dalian Medical University
OBJECTIVES To investigate the relationship between bone mineral
density and left ventricular diastolic function in elderly hypertension
patients.
METHODS Retrospective analysis was performed in 1002 consecutive
hypertension patients, aged over 60, who were admitted to the sec-
ond afﬁliated hospital of Dalian Medical University from December
2013 to February 2015. Bone mineral density (BMD) was measured by
dual X-ray absorptiometry and detected results were shown by T
scores averaged for all four parts. All cases were divided into three
groups based on T scores: Normal bone mass group (n¼269): T-1.0;
Osteopenia group (n¼433): -2.5<T<-1.0; and Osteoporosis group
(n¼300): T-2.5. In order to evaluate the left ventricular diastolic
function in patients, the echocardiogram was used to measure the
early diastolic peak velocity (E) and late diastolic peak velocity (A) of
left ventricle, and then calculate the E/A ratio. E/A 1.0 represents left
ventricular diastolic dysfunction (LVDD), which can be used to assess
the changes in LVDD and to evaluate the relationship with BMD.
ANOVA was applied to analyze the mean of the E/A ratio and Chi-
square test was used to compare LVDD incidence among the indicated
three groups. All cases were divided into two groups based on E/A
ratio. Normal left ventricular diastolic function group (n¼506), E/
A>1;left ventricular diastolic dysfunction group (n¼496), E/A 1.0.
Chi-square test was used to compare abnormal incidence of BMD
between the two groups. Simple linear correlation was used to analyze
the correlation of E/A ratio with each factor. Multiple linear regression
analysis was applied to analyze the independent factors of E/A ratio.
P<0.05 was considered statistically signiﬁcant.
RESULTS 1.The incidence of LVDD of Osteoporosis group (56.3%) was
signiﬁcantly higher than that of Normal bone mass group (44.2%) as
well as Osteopenia group (48%) (p<0.05). And there was no signiﬁcant
difference between Osteopenia group and Normal bone mass group
(p>0.05). The abnormal incidence of BMD of LVDD group (76%) was
higher than normal left ventricular diastolic function group (p<0.05).
2. Reduced BMD of the femoral neck (r¼0.102, p¼0.001) and
increased total cholesterol (r¼-0.067, p¼0.035) both were recognized
as independent variables of LVDD in multinomial regression analysis.
CONCLUSIONS 1. The incidence of LVDD of Osteoporosis group is
signiﬁcantly higher than that of Normal bone mass group. The
abnormal incidence of BMD of LVDD in elderly hypertension patients
is higher than that of normal left ventricular diastolic function.
2. Reduced BMD of the femoral neck and increased total cholesterol
both are recognized as independent variables of LVDD, which can be
referred to be important predictive factors in assessment and evalu-
ation of cardiovascular events.
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The predictable between CAl25 and the rehospitalization rate in CHF patients
Rui Ma
Mengcheng Hospital of Traditional Chinese Medicine
OBJECTIVES To study the relationship between CA 1 25 and the
rehospitalization rate in CHF patients.METHODS 145 patients with CHF were divided into three groups
based on the standard of NYHA.classiﬁcation. The subgroup were
divided according CAl25 levels(35 U / m1) and BNP levels(400 pg / m1).
After 1-.6 months follow-up, the endpoints, mortality and CHF reho-
spitalization were analyzed according the level of CAl25 and BNP.
RESULTS The higher the SeDlm of CAl25, the higher NYHA functional
class[I / 1I(18. 795. 23)U / ml, llI(82. 34_þ24. 37)U / ml, IV(187, 4037.
42)U / ml, P<O. 05], the rate of rehospitalization in patients with CHF
was higher with the increase of selxlm CAl25(P20. 01 1) and BNP(P20.
001). The combination CAl25 with BNP showed more accurately pre-
dictable value of CHF rehospitalization(P¼O. 00012).
CONCLUSIONS Serum levels of CAl25 are associated with the severity
of CHF, which can prognosis the rehospitalization in CHF patients.
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The relation of between pulmonary hypertension and diastolic function in
patients with left ventricular systolic dysfunction
Sang-Hoon Seol, Guang-Won Seo, Pil-Sang Song, Dong-Kie Kim,
Doo-Il Kim
Haeundae Paik hospital
OBJECTIVES Pulmonary hypertension (PH) secondary to left ven-
tricular systolic dysfunction (LVSD) is often a poor prognosis marker
in chronic heart failure. Diastolic ﬁlling pressure abnormalities have
been described in patients with severe PH. The aim of our study was
to assess between diastolic function and PH associated LVSD.
METHODS 425 patients with LV Ejection fraction(EF) 40% were
divided into two groups according to the PH. PH estimated with the
right ventricular systolic pressure. PH was deﬁned systolic pulmonary
artery pressure (PAP) > 45 mmHg at rest. Diastolic parameters
(transmitral ﬂow velocity (E)/mitral annular velocity (e0), mitral valve
deceleration time (DT) and left atrium diameter (LAD) were evaluated.
RESULTS 135 patients had PH, whereas 290 patients had normal. Pa-
tients with PH were with higher E/e0 ratio, lower DT and increased
LAD. In multiple regression analysis, PAP was signiﬁcantly correlated
with E/e0 ratio, DT, gender and LAD. In multivariate analysis, E/e0
ratio> 15(odds ratio: 3.5, P<0.001), LAD (>4.2 cm in male, >3.8 cm in
female) (odds ratio: 2.2, P<0.001), female (odds ratio: 2.1, P¼0.003)
were the independent risk factors for PH in patients with LVSD.
CONCLUSIONS The diastolic echocardiographic parameters may be
important predictors for PH in patients with LVSD.
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Prognostic role of serum C-reactive protein in chronic heart failure: a
systematic review and meta-analysis
Liping Wang, Yong Han, Shanshan Zhou
Department of Internal Medicine-Cardiovascular, Hong Hui Hospital,
Xi’an Jiaotong University College of Medicine, Xi’an, China
OBJECTIVES To aim at investigating serum C-reactive protein (CRP),
a marker of systemic inﬂammation, its role as a prognostic marker in
patients with chronic heart failure (CHF).
METHODS We searched Medline and EMBASE for prospective studies
of patients with CHF that reported clinical outcomes according to
serum CRP levels. A meta-analysis was performed to assess the as-
sociation between CRP levels and prognoses in patients with CHF.
RESULTS A total of eight studies involving 6018 patients were
included in our study. Mean level of CRP was 3.27mg/L at baseline.
Long term follow-up varied from 1 year to 8.7 years. Our pooled re-
sults demonstrated that a high level of CRP was a predictor of mor-
tality (Hazard ratio: 1.86; 95% CI: 1.33 to 3.59; P<0.001) and major
adverse cardiac events (MACE) (Hazard ratio: 2.87, 95% CI: 1.64 to
4.62; P<0.001) in multivariate analysis.
CONCLUSIONS Levels of CRP have predictive value in long term
mortality and MACE of patients with CHF.
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Efﬁcacy of Recombinant Human Brain Natriuretic Peptide in acute
decompensated ischemic heart failure
Zhijun Zhu, Danning Wu
The ll7th Hospital of PLA
OBJECTIVES To explore the clinical efﬁcacies of recombinant human
brain natriuretic peptide(rhBNP) in patients with acute decom-
pensated ischemic heart failure.
